Skip to main content

Table 2 Summary of the isolation and drug resistance profile of GNB in HAP/VAP

From: Multi-drug resistant gram-negative bacterial pneumonia: etiology, risk factors, and drug resistance patterns

Country

Study year

Participants, age group, pneumonia category

Specimen

GNB (%) in culture

Frequently isolated GNB (%)

Decreasing order of resistance, MDR (%)

References

India

2012 to 2014

87, all age, VAP

Tracheal aspirates

88.3%

P. aeruginosa (38.3%), A. baumannii (15.6%), and K. pneumoniae (14.3%)

P. aeruginosa: PEP > CAZ > CN, 73.1%

A. baumannii: CXT > CTX > PEP, 83.3%

K. pneumoniae: CXT > CTX > PEP, 72.2%

[53]

Egypt

2014 to 2015

153, all age, VAP

Tracheal aspirates

87.1%

K. pneumoniae (36.9%), E. coli (21.04%), A. baumannii (14.95%), and P. aeruginosa (14.16%)

K. pneumoniae: CRO > PEP > AZT > CIP/TE > SXT > TZP > CN > AK > IMP, 100%

E. coli: CTR > AZT/PEP > TE > CIP > SXT > CN > TZP > AK > IMP, 98%

A. baumannii: CAZ/CTR/PEP/IMP/LEV/MER/PIP > AK > SXT > CN, 100%

P. aeruginosa: CAR/CRO > CAZ > SXT/PIP/CIP/CN > AK/C > IMP/TZP, 84.84%

[54]

Bangladesh

2015 to 2016

51, all age, VAP

Tracheal aspirates

76.13%

A. baumannii (37.5%), K. pneumoniae (22.7%) and P. aeruginosa (13.6%)

A. baumannii: CRO/CAZ/CTX > AZT/PEP > AK/CN/COT > CIP > IMP > PZP

K. pneumoniae: CRO/CAZ/CTX/PEP > CPR > SXT > CN > AK

P. aeruginosa: PEP/CTX/CRO > CN/SXT/IMP > CAZ/CIP

[55]

Vietnam

2017 to 2018

103, 32 to 94 years old, HAP

Sputum and bronchoalveolar lavage

95.3%

A. baumannii (47.5%), K. pneumoniae (16.2%) and P. aeruginosa (12.1%)

A. baumannii: APS/PEP/CTX/CAZ/CRO/MER/CIP/LEV > PZP > TLV > TOB, 100%

K. pneumoniae: AMP > TOB/PEP/CAZ/SXT > TLV/CRO > AK/CN, 72.7%

P. aeruginosa: CTX > CRO/TLV/CN > TOB/PEP/CIP > AK, 92.3%

[56]

Tanzania

2019 to 2020

269, adult, VAP

Bronchial aspirate

80.1%

P. aeruginosa (24.7%),K. pneumoniae (19.8%), and E. coli (12.4%)

P. aeruginosa: CAZ/CXM/AZT/CIP > CN, 73.9%

K. pneumoniae: CRO > AMC > CIP > PIP, 76.4%

E. coli: CN > CRO > CAZ, 70%

[57]

  1. CAP community-acquired pneumonia, HAP hospital-acquired pneumonia, VAP ventilator-associated pneumonia, ESBL extended-spectrum beta-lactamase, AMP ampicillin, AMC amoxicillin/clavulanate, TOB tobramycin, TZP piperacillin/tazobactam, CRO ceftriaxone, AK amikacin, CXM cefuroxime, CTX cefotaxime, CIP ciprofloxacin, SXT trimethoprim-sulfamethoxazole, CL colistin, CN gentamicin, IMP imipenem, CAZ ceftazidime, TE tetracycline, C chloramphenicol, PEP cefepime, MER meropenem, MIN minocycline, APS ampicillin/sulbactam, TLV ticarcillin/clavulanate, LEV levofloxacin, AZT aztreonam, DO doxycycline